Literature DB >> 28360110

The CFTR trafficking mutation F508del inhibits the constitutive activity of SLC26A9.

Carol A Bertrand1, Shalini Mitra2, Sanjay K Mishra2, Xiaohui Wang2, Yu Zhao3, Joseph M Pilewski4, Dean R Madden3, Raymond A Frizzell2.   

Abstract

Several members of the SLC26A family of anion transporters associate with CFTR, forming complexes in which CFTR and SLC26A functions are reciprocally regulated. These associations are thought to be facilitated by PDZ scaffolding interactions. CFTR has been shown to be positively regulated by NHERF-1, and negatively regulated by CAL in airway epithelia. However, it is unclear which PDZ-domain protein(s) interact with SLC26A9, a SLC26A family member found in airway epithelia. We have previously shown that primary, human bronchial epithelia (HBE) from non-CF donors exhibit constitutive anion secretion attributable to SLC26A9. However, constitutive anion secretion is absent in HBE from CF donors. We examined whether changes in SLC26A9 constitutive activity could be attributed to a loss of CFTR trafficking, and what role PDZ interactions played. HEK293 coexpressing SLC26A9 with the trafficking mutant F508del CFTR exhibited a significant reduction in constitutive current compared with cells coexpressing SLC26A9 and wt CFTR. We found that SLC26A9 exhibits complex glycosylation when coexpressed with F508del CFTR, but its expression at the plasma membrane is decreased. SLC26A9 interacted with both NHERF-1 and CAL, and its interaction with both significantly increased with coexpression of wt CFTR. However, coexpression with F508del CFTR only increased SLC26A9's interaction with CAL. Mutation of SLC26A9's PDZ motif decreased this association with CAL, and restored its constitutive activity. Correcting aberrant F508del CFTR trafficking in CF HBE with corrector VX-809 also restored SLC26A9 activity. We conclude that when SLC26A9 is coexpressed with F508del CFTR, its trafficking defect leads to a PDZ motif-sensitive intracellular retention of SLC26A9.
Copyright © 2017 the American Physiological Society.

Entities:  

Keywords:  CAL; NHERF-1; PDZ domain; chloride channel; intracellular trafficking

Mesh:

Substances:

Year:  2017        PMID: 28360110      PMCID: PMC5495941          DOI: 10.1152/ajplung.00178.2016

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  62 in total

1.  UTP inhibits Na+ absorption in wild-type and DeltaF508 CFTR-expressing human bronchial epithelia.

Authors:  D C Devor; J M Pilewski
Journal:  Am J Physiol       Date:  1999-04

2.  SLC26A9 is expressed in gastric surface epithelial cells, mediates Cl-/HCO3- exchange, and is inhibited by NH4+.

Authors:  Jie Xu; Johanna Henriksnäs; Sharon Barone; David Witte; Gary E Shull; John G Forte; Lena Holm; Manoocher Soleimani
Journal:  Am J Physiol Cell Physiol       Date:  2005-03-30       Impact factor: 4.249

3.  A Golgi-associated PDZ domain protein modulates cystic fibrosis transmembrane regulator plasma membrane expression.

Authors:  Jie Cheng; Bryan D Moyer; Michal Milewski; Johannes Loffing; Masahiro Ikeda; John E Mickle; Garry R Cutting; Min Li; Bruce A Stanton; William B Guggino
Journal:  J Biol Chem       Date:  2001-11-13       Impact factor: 5.157

4.  Regulation by ATP and ADP of CFTR chloride channels that contain mutant nucleotide-binding domains.

Authors:  M P Anderson; M J Welsh
Journal:  Science       Date:  1992-09-18       Impact factor: 47.728

5.  Generation and functional characterization of epithelial cells with stable expression of SLC26A9 Cl- channels.

Authors:  Johanna J Salomon; Stephan Spahn; Xiaohui Wang; Joachim Füllekrug; Carol A Bertrand; Marcus A Mall
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-01-22       Impact factor: 5.464

6.  Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins.

Authors:  C L Ward; R R Kopito
Journal:  J Biol Chem       Date:  1994-10-14       Impact factor: 5.157

7.  IL-17A induces Pendrin expression and chloride-bicarbonate exchange in human bronchial epithelial cells.

Authors:  Kelly M Adams; Valsamma Abraham; Daniel Spielman; Jay K Kolls; Ronald C Rubenstein; Gregory E Conner; Noam A Cohen; James L Kreindler
Journal:  PLoS One       Date:  2014-08-20       Impact factor: 3.240

8.  Ubiquitination and degradation of CFTR by the E3 ubiquitin ligase MARCH2 through its association with adaptor proteins CAL and STX6.

Authors:  Jie Cheng; William Guggino
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

9.  Genetic modifiers of cystic fibrosis-related diabetes.

Authors:  Scott M Blackman; Clayton W Commander; Christopher Watson; Kristin M Arcara; Lisa J Strug; Jaclyn R Stonebraker; Fred A Wright; Johanna M Rommens; Lei Sun; Rhonda G Pace; Sarah A Norris; Peter R Durie; Mitchell L Drumm; Michael R Knowles; Garry R Cutting
Journal:  Diabetes       Date:  2013-05-13       Impact factor: 9.461

10.  PDZK1 and NHERF1 regulate the function of human organic anion transporting polypeptide 1A2 (OATP1A2) by modulating its subcellular trafficking and stability.

Authors:  Jian Zheng; Ting Chan; Florence Shin Gee Cheung; Ling Zhu; Michael Murray; Fanfan Zhou
Journal:  PLoS One       Date:  2014-04-11       Impact factor: 3.240

View more
  27 in total

Review 1.  Recent advances in developing therapeutics for cystic fibrosis.

Authors:  Lisa J Strug; Anne L Stephenson; Naim Panjwani; Ann Harris
Journal:  Hum Mol Genet       Date:  2018-08-01       Impact factor: 6.150

2.  The anion transporter SLC26A9 localizes to tight junctions and is degraded by the proteasome when co-expressed with F508del-CFTR.

Authors:  Yukiko Sato; David Y Thomas; John W Hanrahan
Journal:  J Biol Chem       Date:  2019-10-23       Impact factor: 5.157

3.  SLC26A9 is selected for endoplasmic reticulum associated degradation (ERAD) via Hsp70-dependent targeting of the soluble STAS domain.

Authors:  Patrick G Needham; Jennifer L Goeckeler-Fried; Casey Zhang; Zhihao Sun; Adam R Wetzel; Carol A Bertrand; Jeffrey L Brodsky
Journal:  Biochem J       Date:  2021-12-22       Impact factor: 3.857

4.  Separating the contributions of SLC26A9 and CFTR to anion secretion in primary human bronchial epithelia.

Authors:  Mads B Larsen; Jeannie J Choi; Xiaohui Wang; Michael M Myerburg; Raymond A Frizzell; Carol A Bertrand
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-10-20       Impact factor: 5.464

5.  Structural insights into the gating mechanism of human SLC26A9 mediated by its C-terminal sequence.

Authors:  Ximin Chi; Xueqin Jin; Yun Chen; Xiaoli Lu; Xinyu Tu; Xiaorong Li; Yuanyuan Zhang; Jianlin Lei; Jing Huang; Zhuo Huang; Qiang Zhou; Xiaojing Pan
Journal:  Cell Discov       Date:  2020-08-10       Impact factor: 10.849

6.  A physiologically-motivated model of cystic fibrosis liquid and solute transport dynamics across primary human nasal epithelia.

Authors:  Florencio Serrano Castillo; Carol A Bertrand; Michael M Myerburg; Monica E Shapiro; Timothy E Corcoran; Robert S Parker
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-09-07       Impact factor: 2.745

7.  Increased expression of anion transporter SLC26A9 delays diabetes onset in cystic fibrosis.

Authors:  Anh-Thu N Lam; Melis A Aksit; Briana Vecchio-Pagan; Celeste A Shelton; Derek L Osorio; Arianna F Anzmann; Loyal A Goff; David C Whitcomb; Scott M Blackman; Garry R Cutting
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

8.  CK19 stabilizes CFTR at the cell surface by limiting its endocytic pathway degradation.

Authors:  Xia Hou; Qingtian Wu; Carthic Rajagopalan; Chunbing Zhang; Mohamad Bouhamdan; Hongguang Wei; Xuequn Chen; Khalequz Zaman; Chunying Li; Xiaonan Sun; Song Chen; Raymond A Frizzell; Fei Sun
Journal:  FASEB J       Date:  2019-08-26       Impact factor: 5.834

Review 9.  Recent Progress in CFTR Interactome Mapping and Its Importance for Cystic Fibrosis.

Authors:  Sang Hyun Lim; Elizabeth-Ann Legere; Jamie Snider; Igor Stagljar
Journal:  Front Pharmacol       Date:  2018-01-17       Impact factor: 5.810

10.  SLC26A9 SNP rs7512462 is not associated with lung disease severity or lung function response to ivacaftor in cystic fibrosis patients with G551D-CFTR.

Authors:  Alice C Eastman; Rhonda G Pace; Hong Dang; Melis Atalar Aksit; Briana Vecchio-Pagán; Anh-Thu N Lam; Wanda K O'Neal; Scott M Blackman; Michael R Knowles; Garry R Cutting
Journal:  J Cyst Fibros       Date:  2021-03-02       Impact factor: 5.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.